Equity (Tables)

12 Months Ended

Dec. 31, 2018

Stockholders' Equity Note [Abstract]

Schedule of Convertible Preferred Shares

As of December 31, 2018, the Number of Preferred shares the amount each class is convertible into is below:

	Number of Preferred Stock		Number of underlying Common stock
Series B Convertible Preferred Stock		17,303		3,330,828	*
Series C Convertible Preferred Stock		61,423		1,310,357
Total				4,641,185

* Including the shares of common stock the holders of Series B Convertible Preferred Stock are entitled to receive as cumulative dividends at the rate per share of 15% per annum of the stated value for five years, payable in cash or common stock, at the Company’s discretion, but excluding effect of future conversion price adjustment, if any.

Schedule of Issuance of Warrants to Purchase Common Stock

As of December 31, 2018, the Company has outstanding warrants to purchase an aggregate of 40,746,189 shares of common stock as follows:

	Number of underlying Common stock		Weighted average exercise price
Series A Warrants		52,165	$	175.00
Series B Warrants		122,269	$	70.00
Series D Warrants		40,333,332	$	0.30
Other warrants		238,423	$	88.47
Total Warrants		40,746,189	$	1.25

Schedule of Warrants and Share Options

The following table summarizes information about warrants and share options to employees:

	Year ended December 31
	2018					2017
	Number of warrants and options			Weighted average exercise price		Number of warrants and options			Weighted average exercise price
Outstanding - beginning of period		8,167		$	970.55		9,655		$	891.8
Granted		-					118			32.2
Forfeited		(1,808	)		628.62		(1,606	)		414.05
Exercised		-			-
Outstanding -end of period		6,359		$	1,158.55		8,167		$	970.55
Exercisable at the end of the period		5,111		$	1,414.42		5,295		$	1,431.85

The following table summarizes information about warrants and share options to non-employees:

	Year ended December 31
	2018					2017
	Number of warrants and options			Weighted average exercise price		Number of warrants and options			Weighted average exercise price
Outstanding - beginning of period		49		$	21,238.7		61		$	$31,164.7
Granted		-			-		-			-
Forfeited		(19	)		12,417.53		(12	)		58,165.8
Exercised		-			-		-			-
Outstanding - end of period		30			32,348.23		49		$	21,238.7
Exercisable at the end of the period		28			31,578.81		31		$	$20,874.35

Schedule of Information About Restricted Shares to Employees

The following table summarizes information about restricted shares to employees:

	Year ended December 31
	2018			2017
	Number of restricted shares
Outstanding - beginning of period		1,093			3,755
Granted		-			84
Forfeited		(201	)		(202	)
Vested		(486	)		(2,544	)
Outstanding - end of period		406			1,093

Schedule of Warrants and Options Outstanding and Exercisable

The following table provides additional information about all options outstanding and exercisable:

	Outstanding as of December 31, 2018
Exercise price	Options outstanding		Weighted average remaining contractual life (years)		Options exercisable
$0-$65.1		127		7.68		48
$106.4-$113.75		3,003		7.92		2,002
$166.25-$437.5		3,051		7.56		2,883
$1,180-$19,512.5		86		6.54		86
$25,550-$73,500		122		2.6		119
		6,389		7.62		5,138

Schedule of Assumptions Used in Fair Value of Options Granted to Employees

The following table sets forth the assumptions that were used in determining the fair value of options granted to employees for the year December 31, 2017:

	Year ended December 31
	2017
Expected life		5-6.5 years
Risk-free interest rates		1.78%-2.18	%
Volatility		94.42%-97.62	%
Dividend yield		0	%

Schedule of Allocation of Total Share-based Compensation Expense

The following table summarizes the allocation of total share-based compensation expense in the consolidated statements of operations:

	Year ended December 31
	2018		2017
	($ in thousands)
Cost of revenues	$	4	$	7
Research and development		-		32
Sales and marketing		6		86
General and administrative		60		547
	$	70	$	672